Mesoblast Stock Forecast
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 11:39 AM ET
MESO analyst consensus
Consensus (3 analysts)
buy
Avg. price target
$37.00+174.18%
- Strong buy 2
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Mesoblast (2026-10-07), 3 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $37.00, with a high estimate of $39.00 and a low estimate of $35.00. The average target implies upside of 174.2% from the current price of $13.50.
The spread between the highest and lowest targets is 11.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MESO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 67% |
| Buy | 1 | 33% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $35.00 | +159.36% |
| Average target | $37.00 | +174.18% |
| High target | $39.00 | +189.00% |